Also included are two phase 1 candidates: MED14920, an anti-CD40L-Tn3 fusion protein for primary Sjorgen's syndrome and MEDI7734, an anti-ILT7 mAb drug for myositis. Without the creation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback